Daily Current Affairs

November 20, 2025

Current Affairs

Culmination Ceremony of the 75th Anniversary of the NSS

Context: The Culmination Ceremony of the 75th Anniversary of the National Sample Survey (NSS), along with the observance of World Statistics Day, was recently held in Udaipur, Rajasthan.
The event was organised by the Ministry of Statistics and Programme Implementation (MoSPI), marking the close of a year-long commemoration of India’s statistical system.

Key Highlights of the Ceremony

1. Release of NIC 2025

MoSPI unveiled the National Industrial Classification (NIC) 2025, an updated statistical standard used for classifying economic activities across industries.
It ensures harmonisation with emerging sectors, digital industries, and global classification systems.

2. Launch of the Data Innovation Lab Portal

A new Data Innovation Lab Portal was launched to:

  • Promote innovation in official statistics,
  • Enable applications of AI, machine learning (ML) and advanced analytics,
  • Improve data-driven policy design.

3. Thematic Sessions

Expert sessions focused on:

  • Strengthening field communication strategies,
  • Demonstrating the new Computer-Assisted Personal Interviewing (CAPI) system,
  • Enhancing data quality, timeliness, and transparency.

About the National Sample Survey (NSS)

Origins and Evolution

  • The NSS was established in 1950 following the recommendations of the National Income Committee (1949) chaired by Prasanta Chandra Mahalanobis — regarded as the “Father of Modern Statistics in India.”
  • Over the decades, the NSS has become India’s largest socio-economic survey system, generating nationally representative datasets.

Institutional Changes

  • In 2019, the NSSO (National Sample Survey Office) and the CSO (Central Statistical Office) were merged to form the National Statistical Office (NSO) under MoSPI.
  • After reorganisation, NSS functions as a survey division within the NSO, continuing its mandate of large-scale household surveys.

Core Mandate

The NSS provides high-quality data for:

  • Evidence-based policymaking,
  • Poverty estimation, consumption and labour statistics,
  • Social, demographic, health and sector-specific studies.

Digital Transition

Major technological upgrades include:

  • CAPI (Computer-Assisted Personal Interviewing),
  • e-SIGMA platform for real-time monitoring and validation.

These tools enhance accuracy, minimise manual errors, and improve efficiency of national surveys.

About World Statistics Day

  • Celebrated every five years on 20 October, recognising the importance of reliable and timely statistics for informed global decision-making.
  • The UN General Assembly designated it formally in 2010.
  • Theme 2025: “Driving Change with Quality Statistics and Data for Everyone.”

Conclusion

The 75th anniversary celebrations underscore India’s leadership in building a robust, evolving statistical ecosystem.

The release of NIC 2025, technological upgrades, and innovation-driven platforms reaffirm MoSPI’s commitment to modern, transparent, and high-quality statistics, essential for governance, development planning, and national progress.

Precision Biotherapeutics: India’s Push Toward Next-Gen Personalised Medicine

Context: The Department of Biotechnology (DBT) and BIRAC have placed Precision Biotherapeutics as a national priority under the BioE³ Policy (Bioeconomy for Emerging India Ecosystem). This signals India’s commitment to building capabilities in personalised, gene-based, targeted and molecular therapies — the future of advanced medicine.

What are Precision Biotherapeutics?

Precision biotherapeutics are personalised, molecular-profile-based medical interventions designed using genomics, proteomics, bioinformatics, gene editing, RNA technologies, engineered cells, biologics, and AI-driven drug design.

They represent a shift from the traditional, symptom-based approach to root-cause correction at the level of genes, cells, or molecular pathways.

image 17

Key Technology Pillars

  1. Genomic–Proteomic Profiling
    Identifies patient-specific mutations, biomarkers, and disease signatures enabling personalised drug design.
  2. Gene & Cell Editing Technologies
    Includes CRISPR/Cas9, CAR-T therapy, siRNA, and AAV (Adeno-Associated Virus) vectors for targeted or curative interventions.
  3. mRNA & Nucleic Acid Therapeutics
    Synthetic RNA can act as programmable instructions to produce missing or corrective proteins within cells.
  4. AI-Driven Drug Discovery
    Uses machine learning for molecular docking, target prediction, toxicity screening, and accelerated drug development.

Significance of Precision Biotherapeutics for India

1. Targeted Cure Potential

Unlike general drugs, precision therapies directly treat root-cause mutations.
Example: CRISPR-based thalassemia therapy (Casgevy) approved by the US FDA and UK regulators in 2023.

2. Addressing India’s NCD Burden

Nearly 65% of deaths in India are due to non-communicable diseases. Standard medicine often fails for complex cancers, rare diseases, cardiometabolic disorders; precision medicine provides accurate, personalised solutions.

3. India-Specific Genomic Needs

India’s extreme genetic diversity means therapies developed abroad may not work optimally. Indigenous precision platforms are essential for “India-specific genotype therapies.”

4. Economic & Innovation Opportunity

The global precision biotherapeutics market is projected to exceed USD 22 billion by 2027, creating opportunities for biotech startups, IP creation, clinical trials, and high-value manufacturing.

Challenges in India

  1. High Therapy Cost
    Global gene/cell therapies cost USD 0.5–2 million (e.g., Zolgensma: USD 2.1M), inaccessible to 99% of Indian households.
  2. Regulatory Gaps
    India still lacks a dedicated CDSCO approval pathway for gene, cell, RNA, and genome-edited products.
    Japan’s PMDA regenerative fast-track is a model India could emulate.
  3. Insufficient Manufacturing Capacity
    India has a shortage of GMP-grade viral vector and biologics facilities.
    China, in comparison, runs 800+ ongoing gene/cell therapy trials.
  4. Skill Shortage
    India has only a few trained clinical geneticists compared to 4,000+ medical geneticists in the US.
  5. Ethical & Data Governance Concerns
    India lacks a specific genomic data protection law for biobanks and large datasets like IndiGen and GenomeIndia.

Way Forward

  • Dedicated Regulatory Pathway:
    Establish a CDSCO Gene–Cell Therapy Division with accelerated approvals.
  • Biomanufacturing Expansion:
    Create viral-vector & biologics GMP hubs under PLI-Biopharma.
  • Genomic Data Governance:
    Enact a bio-banking and consent law, aligned with EU-GDPR norms.
  • Affordability & Insurance Models:
    Pilot PM-JAY risk pooling for high-cost therapies.
  • Talent Pipeline:
    Launch national fellowships in genomic medicine & AI-biotech; integrate DBT–IIT–AIIMS translational tracks.
image 18